| Literature DB >> 35381008 |
Ruiqi Huang1, Chenglin Song1, Tao Li1, Caijing Yu1, Tingting Yao1, Haining Gao1, Shicheng Cao1, Xuejie Yi1,2, Bo Chang1.
Abstract
Adipocytes regulate the body's metabolism by secreting adipokines to maintain energy homeostasis. Asprosin is a new type of adipokine, and its relationship with obesity remains controversial. There are a few reports on the effect of long-term exercise on serum asprosin level. This study aimed to investigate the effects of body mass index (BMI) and exercise/sedentary habit on serum asprosin in male college students as well as the relationship between serum asprosin and body composition and related metabolic indicators and provided a basis for further exploration of the biological function of asprosin. Ninety-six male college students were classified into the sedentary habit group (SD; 48) and the special training experience group (ET; 48). Both groups included three subgroups of normal BMI, overweight, and obesity, with 16 people in each subgroup. One-way analysis of variance, analysis of covariance, and Pearson correlation analysis were performed. The results showed that serum asprosin levels in the obesity subgroup were significantly higher than those in the normal and overweight subgroups. Excluding BMI interference, there were no significant differences in serum asprosin between the SD and ET groups; however, there were significant differences in body composition, tumor necrosis factor-α, interleukin-6, and interleukin-10. Asprosin was positively correlated with BMI, body fat percentage, visceral fat area, fasting insulin, insulin resistance homeostasis model, total cholesterol, low-density lipoprotein, tumor necrosis factor-α, interleukin-6, and leptin levels and was negatively correlated with relative lean body mass, relative skeletal muscle mass, high-density lipoprotein, and interleukin-10, and adiponectin levels. In conclusion, serum asprosin is closely related to body weight, body composition, glucose and lipid metabolism, inflammatory response, and fat hormones. Long-term exercise training cannot prevent BMI increase from increasing serum asprosin level. If the influence of BMI is excluded, long-term exercise training does not affect serum asprosin.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35381008 PMCID: PMC8982887 DOI: 10.1371/journal.pone.0265645
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Basic characteristics of all participants.
Comparison of related variables of different BMI grades in SD/ET group.
| SD | ET | |||||
|---|---|---|---|---|---|---|
| Normal (n = 16) | Overweight (n = 16) | Obesity (n = 16) | Normal (n = 16) | Overweight (n = 16) | Obesity (n = 16) | |
| BMI (kg/m2) | 22.01±0.99 | 25.79±0.94 | 32.37±3.22 | 21.58±1.49 | 25.53±0.98 | 30.72±1.76aabb |
| RLBM | 0.84±0.02 | 0.78±0.03 | 0.68±0.05 | 0.87±0.03 | 0.81±0.05 | 0.73±0.04aabb |
| PBF (%) | 16.41±2.22 | 22.42±2.75aa | 32.15±4.57 | 13.47±2.82 | 18.73±4.59 | 26.69±3.53aabb |
| SMI (kg/m2) | 9.53±0.90 | 10.45±1.28 | 10.94±1.61 | 10.57±0.79 | 11.79±0.54 | 11.85±1.62aa |
| RSMM | 0.43±0.04 | 0.41±0.05 | 0.34±0.05 | 0.49±0.02 | 0.46±0.03 | 0.39±0.06aabb |
| VFA (cm2) | 47.81±8.70 | 68.89±8.86 | 130.88±38.58 | 34.24±10.27 | 61.16±18.03 | 100.76±19.86aabb |
| FBG(mmol/L) | 5.02±0.24 | 5.26±0.28 | 5.33±0.29 | 5.09±0.21 | 5.23±0.29 | 5.33±0.48 |
| FINS (mIU/L) | 8.53±1.21 | 10.03±1.09 | 12.30±1.92 | 8.87±0.66 | 10.31±0.56 | 11.88±0.89aabb |
| HOMA-IR(*10-6mol*IU*L-2) | 1.91±0.34 | 2.34±0.26 | 2.92±0.49 | 2.00±0.13 | 2.39±0.20 | 2.81±0.30aabb |
| TC (mmol/L) | 4.01±0.76 | 4.28±0.83 | 5.40±0.90 | 3.78±0.70 | 4.22±0.87 | 4.56±0.70aa |
| TG (mmol/L) | 0.72±0.19 | 0.75±0.16 | 1.00±0.40 | 0.70±0.21 | 0.74±0.24 | 0.88±0.32 |
| HDL-C (mmol/L) | 1.46±0.15 | 1.29±0.16 | 1.14±0.13 | 1.50±0.13 | 1.32±0.16 | 1.17±0.15aab |
| LDL-C (mmol/L) | 2.10±0.32 | 2.70±1.26 | 3.36±1.09 | 2.05±0.70 | 2.51±0.49 | 2.92±1.04a |
| TNF-α (pg/mL) | 17.43±3.75 | 25.35±4.61 | 30.16±5.93 | 16.40±2.70 | 22.63±3.83 | 25.51±2.72aabb |
| IL-6 (pg/mL) | 5.80±0.68 | 6.52±0.93 | 7.00±1.11 | 5.27±0.37 | 5.63±0.40 | 5.97±0.78aa |
| IL-10 (pg/mL) | 894.57±69.02 | 791.14±81.16 | 715.63±105.37 | 943.50±67.61 | 837.01±58.06 | 777.50±85.68aab |
| ADPN (ng/mL) | 2621.33±418.68 | 2225.50±886.06 | 1581.33±354.91 | 2969.14±736.15 | 2218.01±841.47 | 1678.01±574.08aab |
| Leptin (ng/mL) | 1.43±0.06 | 1.44±0.06 | 2.31±0.61 | 1.35±0.04 | 1.50±0.16 | 2.25±0.54aabb |
| ASP (ng/mL) | 23.77±11.56 | 33.11±22.89 | 82.06±44.99 | 20.09±11.96 | 30.49±18.61 | 92.98±46.39aabb |
Note: BMI: body mass index; RLBM: relative lean body mass; PBF: body fat percentage; SMI: skeletal muscle index; RSMM: relative skeletal muscle mass; VFA: visceral fat area; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: insulin resistance homeostasis model; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein; TNF-α: tumor necrosis factor α; IL-6: interleukin 6; IL-10: interleukin 10; ADPN: adiponectin; ASP: asprosin.
acompared with the normal BMI group
bcompared with the overweight BMI group.
P<0.05 indicates a significant difference; P<0.01 indicates an extremely significant difference.
Analysis of covariance comparison of related variables between SD and ET groups.
| SD (n = 48) | ET (n = 48) |
| |
|---|---|---|---|
| RLBM | 0.76±0.07 | 0.80±0.07aa | <0.001 |
| PBF (%) | 23.66±7.29 | 19.63±6.59aa | <0.001 |
| SMI (kg/m2) | 10.31±1.44 | 11.41±1.25aa | <0.001 |
| RSMM | 0.39±0.06 | 0.45±0.06aa | <0.001 |
| VFA (cm2) | 82.53±42.76 | 65.38±32.30aa | 0.001 |
| FBG(mmol/L) | 5.20±0.30 | 5.22±0.36 | 0.666 |
| FINS (mIU/L) | 10.29±2.15 | 10.35±1.43 | 0.332 |
| HOMA-IR(*10-6mol*IU*L-2) | 2.39±0.56 | 2.41±0.40 | 0.363 |
| TC (mmol/L) | 4.56±1.03 | 4.19±0.82 | 0.084 |
| TG (mmol/L) | 0.82±0.30 | 0.77±0.27 | 0.524 |
| HDL-C (mmol/L) | 1.30±0.20 | 1.33±0.20 | 0.692 |
| LDL-C (mmol/L) | 2.72±1.11 | 2.49±0.85 | 0.424 |
| TNF-α (pg/mL) | 24.31±7.15 | 21.51±4.92a | 0.032 |
| IL-6 (pg/mL) | 6.44±1.06 | 5.62±0.63aa | <0.001 |
| IL-10 (pg/mL) | 800.44±114.62 | 852.67±100.09a | 0.023 |
| ADPN (ng/mL) | 2142.72±738.79 | 2288.38±898.24 | 0.641 |
| Leptin (ng/mL) | 1.72±0.54 | 1.70±0.51 | 0.569 |
| ASP (ng/mL) | 46.31±39.75 | 47.85±44.24 | 0.377 |
Note: BMI: body mass index; RLBM: relative lean body mass; BFP: body fat percentage; SMI: skeletal muscle index; RSMM: relative skeletal muscle mass; VFA: visceral fat area; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: insulin resistance homeostasis model; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein; TNF-α: tumor necrosis factor α; IL-6: interleukin 6; IL-10: interleukin 10; ADPN: adiponectin; ASP: asprosin.
P<0.05 means significant difference, represented by a; and P<0.01 means extremely significant difference, represented by aa.
Correlation between serum ASP levels and other variables.
| All (n = 96) | ||
|---|---|---|
| R | p | |
| BMI (kg/m2) | 0.551 | <0.001 |
| RLBM | -0.518 | <0.001 |
| BFP (%) | 0.520 | <0.001 |
| RSMM | -0.398 | 0.005 |
| VFA (cm2) | 0.444 | 0.002 |
| FINS (mIU/L) | 0.535 | <0.001 |
| HOMA-IR (*10-6mol*IU*L-2) | 0.537 | <0.001 |
| TC (mmol/L) | 0.294 | 0.043 |
| HDL-C (mmol/L) | -0.481 | <0.001 |
| LDL-C (mmol/L) | 0.574 | <0.001 |
| TNF-α (pg/mL) | 0.410 | <0.001 |
| IL-6 (pg/mL) | 0.455 | 0.001 |
| IL-10 (pg/mL) | -0.280 | 0.006 |
| ADPN (ng/mL) | -0.457 | <0.001 |
| Leptin (ng/mL) | 0.417 | <0.001 |
Note: a indicates the degree of correlation; P<0.05 indicates that the correlation between variables is reliable.